Royal Bank of Canada
AQST icon

Royal Bank of Canada’s Aquestive Therapeutics AQST Stock Holding History

Royal Bank of Canada’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$120K Buy
28,951
+16,525
+133% +$67.1K ﹤0.01% 5022
2025
Q4 		$80K Sell
12,426
-350,978
-97% -$2.19M ﹤0.01% 5315
2025
Q3 		$2.03M Buy
363,404
+21,985
+6% +$95.1K ﹤0.01% 3393
2025
Q2 		$1.13M Buy
341,419
+336,435
+6,750% +$965K ﹤0.01% 3797
2025
Q1 		$15K Sell
4,984
-2,216
-31% -$6.71K ﹤0.01% 6004
2024
Q4 		$26K Sell
7,200
-3,125
-30% -$14.4K ﹤0.01% 5996
2024
Q3 		$51K Buy
10,325
+3,340
+48% +$13K ﹤0.01% 5686
2024
Q2 		$18K Sell
6,985
-23,015
-77% -$76.9K ﹤0.01% 6108
2024
Q1 		$128K Buy
+30,000
New +$99.9K ﹤0.01% 5043
2023
Q3 		– Sell
-4,000
Closed -$7K – 7051
2023
Q2 		$7K Buy
+4,000
New +$7.24K ﹤0.01% 6561
2022
Q4 		– Sell
-20,087
Closed -$23K – 7194
2022
Q3 		$23K Buy
+20,087
New +$22.7K ﹤0.01% 6082
2022
Q2 		– Sell
-1,600
Closed -$4K – 7342
2022
Q1 		$4K Sell
1,600
-2,330
-59% -$6.8K ﹤0.01% 7301
2021
Q4 		$15K Buy
3,930
+1,330
+51% +$6.67K ﹤0.01% 6905
2021
Q3 		$11K Sell
2,600
-4,674
-64% -$18.3K ﹤0.01% 6924
2021
Q2 		$29K Buy
7,274
+2,585
+55% +$10.3K ﹤0.01% 6357
2021
Q1 		$25K Buy
4,689
+1,905
+68% +$10.1K ﹤0.01% 6296
2020
Q4 		$15K Buy
2,784
+648
+30% +$3.88K ﹤0.01% 6185
2020
Q3 		$10K Buy
2,136
+536
+34% +$3.5K ﹤0.01% 5919
2020
Q2 		$8K Sell
1,600
-11,969
-88% -$55.1K ﹤0.01% 5897
2020
Q1 		$29K Sell
13,569
-27,408
-67% -$104K ﹤0.01% 5405
2019
Q4 		$239K Buy
40,977
+11,485
+39% +$59.8K ﹤0.01% 4516
2019
Q3 		$94K Sell
29,492
-29,817
-50% -$112K ﹤0.01% 4823
2019
Q2 		$249K Buy
+59,309
New +$304K ﹤0.01% 4334
2018
Q4 		– Sell
-521
Closed -$9K – 6720
2018
Q3 		$9K Buy
+521
New +$8.59K ﹤0.01% 6011

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Royal Bank of Canada's AQST Position: Q1 2026 in Review

Royal Bank of Canada increased its Aquestive Therapeutics (AQST) stake by 133% in Q1 2026, buying an estimated $67.1K and bringing the position to 28,951 shares worth $120K. The position accounts for ﹤0.01% of the portfolio, ranked #5022.

Royal Bank of Canada first reported a position in AQST in Q3 2018 and has held it in 24 quarters since. The position peaked at $2.03M in Q3 2025. 179 funds tracked by Wall St. Rank hold AQST as of Q1 2026.

  • Royal Bank of Canada held 28,951 shares of Aquestive Therapeutics worth $120K as of Q1 2026.
  • Royal Bank of Canada bought 16,525 Aquestive Therapeutics shares in Q1 2026, an estimated $67.1K.
  • Aquestive Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #5022 holding.
  • Royal Bank of Canada first reported a position in Aquestive Therapeutics in Q3 2018 and has held it in 24 quarters since.
  • Royal Bank of Canada's Aquestive Therapeutics position peaked at $2.03M in Q3 2025.
  • 179 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.